Loading...
New

Radiodermatitis Market by Product (Topical, Oral Drugs, and Dressings) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2019-2027

A04148
Pages: 213
Aug 2020 | 1656 Views
 
Author(s) : Surabhi Pandey, Smita Nerkar , Onkar Sumant
Tables: 131
Charts: 58
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Radiodermatitis Market

Request Now !

The global radiodermatitis market size was valued at $477.48 million in 2019, and is projected to reach $609.68 million by 2027, registering a CAGR of 4.1% from 2020 to 2027.

Radiodermatitis, also known as radiation dermatitis, is a condition caused by radiation therapy used for cancer treatment. Radiodermatitis occurs in approximately 95% of patients receiving radiation therapy, especially patients with breast cancer, head & neck cancer, skin cancer, lung cancer, or sarcoma. Cumulative daily doses of radiation to the treatment field or target site on the body inhibits normal skin repopulation and fades skin integrity at and around the radiation field. Radiodermatitis may be acute or chronic and includes localized erythema, skin peeling (desquamation), hair loss (epilation), fibrosis, necrosis, and other related conditions. Acute radiodermatitis have been classified into four levels; grade 1 (mild erythema), grade 2 (dry desquamation), grade 3 (severe moist desquamation), and grade 4 (life threatening and chronic). Radiodermatitis is generally treated with topical agents such as corticosteroids; hydrophilic creams, topical antibiotics; oral medications like oral corticosteroids, oral analgesics, anti-inflammatory agents, and antibiotics; and dressings. 

Radiodermatitis-Market-2020-2027

Get more information on this report : Request Sample Pages

 

The COVID-19 pandemic has disrupted each aspect of healthcare provision including cancer care. The radiodermatitis market has moderate impact from the present corona virus pandemic. In fact, during the pandemic, patients with cancer represent a high-risk group as they require hospital visits for their radiation therapy doses, which is one of the few treatment modalities available for cancer treatment. During the COVID-19 pandemic, leading cancer institutions reported that radiotherapy has proved to be most appropriate and safe treatment option. Whereas, radiation dermatitis is a common side effect of radiotherapy, which can damage skin cells as it fights cancer cells. Hence, demand for radiodermatitis products is anticipated to increase simultaneously, which further boosts growth of the market. At certain point, the radiodermatitis market is expected to register a decline during the forecast period, owing to various manufacturers in radiodermatitis facing issues in supply of their products.

Growth of the global radiodermatitis market is majorly driven by increase in prevalence of cancer and rise in adoption of radiotherapy for treatment globally. In addition, increase in geriatric population further fuels growth of the radiodermatitis market. However, high cost associated with radiodermatitis treatment is anticipated to restrict growth of the market. On the contrary, increase in demand for reduction of side effects associated with radiation therapy is expected to offer lucrative opportunities for the market expansion during the forecast period.

The global radiodermatitis market is segmented into product, distribution channel, and region. On the basis of product, it is fragmented into topical, oral drugs, and dressings. The topical products segment is further divided into corticosteroids, hydrophilic creams, topical antibiotics, and others. The dressings segment is divided into hydrogel and hydrocolloid dressings, no sting barrier film, honey impregnated gauze, silicone coated, and others. By distribution channel, the market categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Product segment review

By product, the topical segment accounted for the largest radiodermatitis market share in 2019, and is expected to maintain its dominance during the forecast period, owing to easier application, cost-effectiveness, and its bioavailability. However, the dressing segment is projected to grow with the highest CAGR from 2020 to 2027, owing to presence of a wide range of dressing products in the market and rise in demand for modern wound care options. These products include hydrogel & hydrocolloid, foam-based, silicone-coated, and silver-leaf dressings. Owing to advantages associated with it, hydrogel & hydrocolloid dressings are commonly used in treatment of radiation burns.

Radiodermatitis Market
By Product

Your browser does not support the canvas element.

Topical segment holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Distribution channel segment review

On the basis of distribution channel, the retail pharmacy segment was the largest revenue generating segment in the market in 2019, owing to availability of affordable product options, locality stores, and availability of generic form of drugs, which are cost effective and relatively cheaper than branded drugs. However, the online pharmacy segment is anticipated to be the highest growing segment with the highest CAGR from 2020 to 2027, owing to increase in convenience for patients, as it provides home delivery of products. In addition, patients can get discounts on radiodermatitis products via online pharmacies, which further boosts growth of the market.

Radiodermatitis Market
By Distribution Channel

Your browser does not support the canvas element.

Online Pharmacy segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Region segment review

Asia-Pacific is estimated to dominate the market throughout the analysis period, owing to rise in disposable income, increase in expenditure on healthcare, rise in prevalence of cancer patients, and growth in adoption of advanced healthcare products. However, North America is expected to register highest CAGR during the forecast period, owing to inclusion of radiodermatitis products in reimbursement healthcare policy, rise in number of cancer patients, surge in demand for radiation therapy, and high expenditure in the healthcare sector.

Radiodermatitis Market
By Region

2027
Asia-pacific 
North America
Europe
Lamea

North America would exhibit the highest CAGR of 5.1% during 2020-2027.

Get more information on this report : Request Sample Pages

Some of the key players operating in the radiodermatitis market include 3M Company, Bausch Health Companies Inc, Bayer Ag, BMG Pharma SPA, Convatec Group Plc, Glaxosmithkline Plc, Helsinn Healthcare SA, Molnlycke Health Care, Mylan N.V., Smith & Nephew Plc, and Stratpharma Ag.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current radiodermatitis market trends and future estimations from 2020 to 2027, which assists in identifying prevailing radiodermatitis market opportunities. 
  • An in-depth analysis of various regions is likely to provide a detailed understanding of the current trends to the stakeholders to formulate region-specific plans.
  • Comprehensive analysis of factors that drive and restrain growth of the radiodermatitis market are provided.
  • Key regulatory guidelines for the radiodermatitis market are critically dealt according to region.
  • A deep dive analysis of various regions provides insights that would allow companies to strategically plan their business moves.

Key Market Segments

By Product

  • Topical
    • Corticosteroids
    • Hydrophilic Creams
    • Topical Antibiotics
    • Others 
  • Oral Drugs
  • Dressings
    • Hydrogel and Hydrocolloid Dressings
    • No Sting Barrier Film
    • Honey Impregnated Gauze
    • Silicone Coated
    • Others

By Distribution Channel 

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.3.1.Top winning strategies

3.4.Top player positioning, 2019
3.5.Porter’s five forces analysis
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Growth in the geriatric population
3.6.1.2.Increase in prevalence of cancer
3.6.1.3.Rise in the adoption of radiotherapy

3.6.2.Restraints

3.6.2.1.Higher radiodermatitis cost

3.6.3.Opportunity

3.6.3.1.Increase in demand for reduction of side effects associated with radiation therapy

3.7.COVID-19 impact analysis for radiodermatitis market
3.8.Reimbursement scenario
3.9.Approved radiodermatitis products with prices
3.10.Pipeline analysis

CHAPTER 4:GLOBAL RADIODERMATITIS MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Topical

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Corticosteroids

4.2.2.1.1.Market size and forecast

4.2.2.2.Hydrophilic creams

4.2.2.2.1.Market size and forecast

4.2.2.3.Topical antibiotics

4.2.2.3.1.Market size and forecast

4.2.2.4.Others

4.2.2.4.1.Market size and forecast

4.2.3.Market size and forecast, by region
4.2.4.Market analysis, by country

4.3.Oral drugs

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Dressings

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type

4.4.2.1.Hydrogel and hydrocolloid dressings

4.4.2.1.1.Market size and forecast

4.4.2.2.No sting barrier film

4.4.2.2.1.Market size and forecast

4.4.2.3.Honey impregnated gauze

4.4.2.3.1.Market size and forecast

4.4.2.4.Silicone coated

4.4.2.4.1.Market size and forecast

4.4.2.5.Others

4.4.2.5.1.Market size and forecast

4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country

CHAPTER 5:RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL

5.1.Overview

5.1.1.Market size and forecast

5.2.Hospital pharmacy

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Retail pharmacy

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Online pharmacy

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:GLOBAL RADIODERMATITIS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by country

6.2.2.1.U.S. radiodermatitis market, by product
6.2.2.2.U.S. radiodermatitis market, by distribution channel
6.2.2.3.Canada radiodermatitis market, by product
6.2.2.4.Canada radiodermatitis market, by distribution channel
6.2.2.5.Mexico radiodermatitis market, by product
6.2.2.6.Mexico radiodermatitis market, by distribution channel

6.2.3.North America radiodermatitis market, by product
6.2.4.North America Radiodermatitis Market, by distribution channel

6.3.Europe

6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by country

6.3.2.1.Germany radiodermatitis market, by product
6.3.2.2.Germany radiodermatitis market, by distribution channel
6.3.2.3.France radiodermatitis market, by product
6.3.2.4.France radiodermatitis market, by distribution channel
6.3.2.5.UK radiodermatitis market, by product
6.3.2.6.UK radiodermatitis market, by distribution channel
6.3.2.7.Italy radiodermatitis market, by product
6.3.2.8.Italy radiodermatitis market, by distribution channel
6.3.2.9.Spain radiodermatitis market, by product
6.3.2.10.Spain radiodermatitis market, by distribution channel
6.3.2.11.Rest of Europe radiodermatitis market, by product
6.3.2.12.Rest of Europe radiodermatitis market, by distribution channel

6.3.3.Europe radiodermatitis market, by product
6.3.4.Europe radiodermatitis market, by distribution channel

6.4.Asia-Pacific

6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by country

6.4.2.1.Japan radiodermatitis market, by product
6.4.2.2.Japan radiodermatitis market, by distribution channel
6.4.2.3.China radiodermatitis market, by product
6.4.2.4.China radiodermatitis market, by distribution channel
6.4.2.5.India radiodermatitis market, by product
6.4.2.6.India radiodermatitis market, by distribution channel
6.4.2.7.Australia radiodermatitis market, by product
6.4.2.8.Australia radiodermatitis market, by distribution channel
6.4.2.9.South Korea radiodermatitis market, by product
6.4.2.10.South Korea radiodermatitis market, by distribution channel
6.4.2.11.Rest of Asia-Pacific radiodermatitis market, by product
6.4.2.12.Rest of Asia-Pacific radiodermatitis market, by distribution channel

6.4.3.Asia-Pacific radiodermatitis market, by product
6.4.4.Asia-Pacific radiodermatitis market, by distribution channel

6.5.LAMEA

6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by country

6.5.2.1.Brazil radiodermatitis market, by product
6.5.2.2.Brazil radiodermatitis market, by distribution channel
6.5.2.3.Saudi Arabia radiodermatitis market, by product
6.5.2.4.Saudi Arabia radiodermatitis market, by distribution channel
6.5.2.5.South Africa radiodermatitis market, by product
6.5.2.6.South Africa radiodermatitis market, by distribution channel
6.5.2.7.Rest of LAMEA radiodermatitis market, by product
6.5.2.8.Rest of LAMEA radiodermatitis market, by distribution channel

6.5.3.LAMEA radiodermatitis market, by product
6.5.4.LAMEA radiodermatitis market, by distribution channel

CHAPTER 7:COMPANY PROFILES

7.1.THE 3M COMPANY

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.BAYER AG.

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance

7.3.BAUSCH HEALTH COMPANIES INC.

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance

7.4.BMG PHARMA S.P.A.

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio

7.5.CONVATEC GROUP PLC.

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments

7.6.GLAXOSMITHKLINE PLC

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.

7.7.HELSINN HEALTHCARE SA

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Key strategic moves and developments

7.8.MOLNLYCKE HEALTH CARE AB

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance

7.9.MYLAN N.V.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio

7.9.5.Business performance

7.10.STRATPHARMA AG

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments

7.11.SMITH & NEPHEW PLC

7.11.1.Company overview
7.11.2.Company snapshot
7.11.3.Operating business segments
7.11.4.Product portfolio
7.11.5.Business performance

LIST OF TABLES

TABLE 01.SEVERITY OF RADIATION DERMATITIS, BY GRADES
TABLE 02.APPROVED RADIODERMATITIS PRODUCT WITH PRICES
TABLE 03.PIPLINE ANALYSIS
TABLE 04.RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 05.RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 06.RADIODERMATITIS MARKET FOR TOPICAL, BY TYPE, 2019–2027 ($MILLION)
TABLE 07.RADIODERMATITIS MARKET FOR TOPICAL, BY TYPE, 2019–2027 (MILLION UNITS)
TABLE 08.RADIODERMATITIS MARKET FOR TOPICAL, BY REGION, 2019–2027 ($MILLION)
TABLE 09.RADIODERMATITIS MARKET, FOR TOPICAL, BY REGION, 2019–2027 (MILLION UNITS)
TABLE 10.RADIODERMATITIS MARKET FOR ORAL DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 11.RADIODERMATITIS MARKET FOR ORAL DRUGS, BY REGION, 2019–2027 (MILLION UNITS)
TABLE 12.RADIODERMATITIS MARKET FOR DRESSINGS, BY TYPE, 2019–2027 ($MILLION)
TABLE 13.RADIODERMATITIS MARKET FOR DRESSINGS, BY TYPE, 2019–2027 (MILLION UNITS)
TABLE 14.RADIODERMATITIS MARKET, FOR DRESSING, BY REGION, 2019–2027 ($MILLION)
TABLE 15.RADIODERMATITIS MARKET FOR DRESSINGS, BY REGION, 2019–2027 (MILLION UNIT)
TABLE 16.RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 17.RADIODERMATITIS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 18.RADIODERMATITIS MARKET FOR RETAIL PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 19.RADIODERMATITIS MARKET FOR ONLINE PHARMACY, BY REGION, 2019–2027 ($MILLION)
TABLE 20.RADIODERMATITIS MARKET, BY REGION, 2019–2027 ($MILLION)
TABLE 21.RADIODERMATITIS MARKET, BY REGION, 2019–2027 (MILLION UNITS)
TABLE 22.NORTH AMERICA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 23.NORTH AMERICA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 24.U.S. RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 25.U.S. RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 26.U.S. RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 27.CANADA RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 28.CANADA RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 (MILLION UNITS)
TABLE 29.CANADA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 30.MEXICO RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 31.MEXICO RADIODERMATITIS MARKET, BY PRODUCT, 2019-2027 (MILLION UNITS)
TABLE 32.MEXICO RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 33.NORTH AMERICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 34.NORTH AMERICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 35.NORTH AMERICA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 36.EUROPE RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 37.EUROPE RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 38.GERMANY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 39.GERMANY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 40.GERMANY RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 41.FRANCE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 42.FRANCE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 43.FRANCE RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 44.UK RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 45.UK RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 46.UK RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 47.ITALY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 48.ITALY RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 49.ITALY RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 50.SPAIN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 51.SPAIN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 52.SPAIN RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 53.REST OF EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 55.REST OF EUROPE RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 56.EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 57.EUROPE RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 58.EUROPE RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 61.JAPAN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 62.JAPAN RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 63.JAPAN RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 64.CHINA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 65.CHINA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 66.CHINA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 67.INDIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 68.INDIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 69.INDIA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 70.AUSTRALIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 71.AUSTRALIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 72.AUSTRALIA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 73.SOUTH KOREA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 74.SOUTH KOREA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 75.SOUTH KOREA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 76.REST OF ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 77.REST OF ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 78.REST OF ASIA-PACIFIC RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 79.ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 80.ASIA-PACIFIC RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 81.ASIA-PACIFIC RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 82.LAMEA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 83.LAMEA RADIODERMATITIS MARKET, BY COUNTRY, 2019–2027 (MILLION UNITS)
TABLE 84.BRAZIL RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 85.BRAZIL RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 86.BRAZIL RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 87.SAUDI ARABIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 88.SAUDI ARABIA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 89.SAUDI ARABIA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 90.SOUTH AFRICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 91.SOUTH AFRICA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 92.SOUTH AFRICA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 93.REST OF LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 94.REST OF LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 95.REST OF LAMEA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 96.LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 97.LAMEA RADIODERMATITIS MARKET, BY PRODUCT, 2019–2027 (MILLION UNITS)
TABLE 98.LAMEA RADIODERMATITIS MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 99.3M: COMPANY SNAPSHOT
TABLE 100.3M: OPERATING SEGMENTS
TABLE 101.3M: PRODUCT PORTFOLIO
TABLE 102.BAYER: COMPANY SNAPSHOT
TABLE 103.BAYER: OPERATING SEGMENTS
TABLE 104.BAYER: PRODUCT PORTFOLIO
TABLE 105.BAUSCH: COMPANY SNAPSHOT
TABLE 106.BAUSCH: OPERATING SEGMENTS
TABLE 107.BAUSCH: PRODUCT PORTFOLIO
TABLE 108.BMG PHARMA: COMPANY SNAPSHOT
TABLE 109.BMG PHARMA: OPERATING SEGMENTS
TABLE 110.BMG PHARMA: PRODUCT PORTFOLIO
TABLE 111.CONVATEC: COMPANY SNAPSHOT
TABLE 112.CONVATEC: OPERATING SEGMENTS
TABLE 113.CONVATEC: PRODUCT PORTFOLIO
TABLE 114.GSK: COMPANY SNAPSHOT
TABLE 115.GSK: OPERATING SEGMENTS
TABLE 116.GSK: PRODUCT PORTFOLIO
TABLE 117.HELSINN: COMPANY SNAPSHOT
TABLE 118.HELSINN: OPERATING SEGMENTS
TABLE 119.HELSINN: PRODUCT PORTFOLIO
TABLE 120.MOLNLYCKE: COMPANY SNAPSHOT
TABLE 121.MOLNLYCKE: OPERATING SEGMENTS
TABLE 122.MOLNLYCKE: PRODUCT PORTFOLIO
TABLE 123.MYLAN: COMPANY SNAPSHOT
TABLE 124.MYLAN: OPERATING SEGMENTS
TABLE 125.MYLAN: PRODUCT PORTFOLIO
TABLE 126.STRATPHARMA: COMPANY SNAPSHOT
TABLE 127.STRATPHARMA: OPERATING SEGMENTS
TABLE 128.STRATPHARMA: PRODUCT PORTFOLIO
TABLE 129.SMITH & NEPHEW: COMPANY SNAPSHOT
TABLE 130.SMITH & NEPHEW: OPERATING SEGMENTS
TABLE 131.SMITH & NEPHEW: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.RADIODERMATITIS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS IN RADIODERMATITIS MARKET
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2016-2019*
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2019* (%)
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2016-2019*
FIGURE 06.TOP PLAYER POSITIONING, 2019
FIGURE 07.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE THREAT OF SUBSTITUTION
FIGURE 11.MODERATE COMPETITIVE RIVALRY
FIGURE 12.RADIODERMATITIS MARKET FOR CORTICOSTEROIDS, 2019–2027 ($MILLION)
FIGURE 13.RADIODERMATITIS MARKET FOR CORTICOSTEROIDS, 2019–2027 (MILLION UNITS)
FIGURE 14.RADIODERMATITIS MARKET FOR HYDROPHILIC CREAMS, 2019–2027 ($MILLION)
FIGURE 15.RADIODERMATITIS MARKET FOR HYDROPHILIC CREAMS, 2019–2027 (MILLION UNITS)
FIGURE 16.RADIODERMATITIS MARKET FOR TOPICAL ANTIBIOTICS, 2019–2027 ($MILLION)
FIGURE 17.RADIODERMATITIS MARKET FOR TOPICAL ANTIBIOTICS, 2019–2027 (MILLION UNITS)
FIGURE 18.RADIODERMATITIS MARKET FOR OTHER TOPICALS, 2019–2027 ($MILLION)
FIGURE 19.RADIODERMATITIS MARKET FOR OTHER TOPICALS, 2019–2027 (MILLION UNITS)
FIGURE 20.COMPARATIVE ANALYSIS OF RADIODERMATITIS MARKET, FOR TOPICAL BY COUNTRY,  2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF RADIODERMATITIS MARKET FOR ORAL DRUGS, BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.RADIODERMATITIS MARKET FOR DRESSINGS, BY HYDROGEL AND HYDROCOLLOID DRESSINGS, 2019–2027 ($MILLION)
FIGURE 23.RADIODERMATITIS MARKET FOR DRESSINGS, BY HYDROGEL AND HYDROCOLLOID DRESSINGS, 2019–2027 (MILLION UNITS)
FIGURE 24.RADIODERMATITIS MARKET FOR DRESSINGS, BY NO STING BARRIER FILM, 2019–2027 ($MILLION)
FIGURE 25.RADIODERMATITIS MARKET FOR DRESSINGS, BY NO STING BARRIER FILM, 2019–2027 (MILLION UNITS)
FIGURE 26.RADIODERMATITIS MARKET FOR DRESSINGS, BY HONEY IMPREGNATED GAUZE, 2019–2027 ($MILLION)
FIGURE 27.RADIODERMATITIS MARKET FOR DRESSINGS, BY HONEY IMPREGNATED GAUZE, 2019–2027 (MILLION UNITS)
FIGURE 28.RADIODERMATITIS MARKET FOR DRESSINGS, BY SILICONE COATED, 2019–2027 ($MILLION)
FIGURE 29.RADIODERMATITIS MARKET FOR DRESSINGS, BY SILICONE COATED, 2019–2027 (MILLION UNITS)
FIGURE 30.RADIODERMATITIS MARKET FOR DRESSINGS, BY OTHER DRESSINGS, 2019–2027 ($MILLION)
FIGURE 31.RADIODERMATITIS MARKET FOR DRESSINGS, BY OTHER DRESSINGS, 2019–2027 (MILLION UNITS)
FIGURE 32.COMPARATIVE ANALYSIS OF RADIODERMATITIS MARKET, FOR DRESSING BY COUNTRY,  2019 & 2027 (%)
FIGURE 33.COMPARATIVE ANALYSIS OF RADIODERMATITIS MARKET, FOR HOSPITAL PHARMACY BY COUNTRY, 2019 & 2027 (%)
FIGURE 34.COMPARATIVE ANALYSIS OF RADIODERMATITIS MARKET, FOR RETAIL PHARMACY, BY COUNTRY, 2019 & 2027 (%)
FIGURE 35.COMPARATIVE ANALYSIS OF RADIODERMATITIS MARKET, FOR ONLINE PHARMACY BY COUNTRY, 2019 & 2027 (%)
FIGURE 36.3M: NET SALES, 2019–2019 ($MILLION)
FIGURE 37.3M: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.3M: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.BAYER: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.BAYER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.BAYER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.BAUSCH: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.BAUSCH: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 44.BAUSCH: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 45.CONVATEC: NET SALES, 2017–2019 ($MILLION)
FIGURE 46.CONVATEC: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 47.CONVATEC: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 48.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 49.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 50.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 51.MOLNLYCKE: NET SALES, 2019–2019 ($MILLION)
FIGURE 52.MOLNLYCKE: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 53.MOLNLYCKE: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 54.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 55.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 56.SMITH & NEPHEW: NET SALES, 2017–2019 ($MILLION)
FIGURE 57.SMITH & NEPHEW: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 58.SMITH & NEPHEW: REVENUE SHARE, BY REGION, 2019 (%)

 
 

In accordance to several interviews conducted, utilization of dressings is expected to witness a significant growth, owing to presence of a wide range of products in the market. Moreover, topical products reduce the risk of microbial transmission and shield the skin against abrasive materials. Corticosteroids, hydrophilic creams, and topical antibiotics are some of the major products under this segment.

Furthermore, rise in demand for radiodermatitis products is majorly driven by increase in prevalence of cancer and rise in adoption of radiotherapy for treatment. In addition, expansion of drug pipeline is anticipated to include a growing number of clinical trials performed to determine effectiveness of a wide variety of treatment products for radiodermatitis. However, high cost associated with radiodermatitis treatment and lack of reimbursement policies in developing countries is anticipated to restrict growth of the market. Presently, topical and dressings segments are the most preferred options by patients suffering from radiodermatitis. In addition, use of radiodermatitis products is highest in Asia-Pacific, owing to rise in prevalence of cancer patients and comprehensive partnerships undertaken by key players to increase their capacity to extend product range.  Moreover, established pharmaceutical companies in this region are extensively involved in commercialization of their products and promotion of their use amongst end users. Furthermore, North America is driven by large R&D investments, deployed by multinational players and their emphasis on maintaining a sustainable market place. In addition, high disposable income and advanced healthcare infrastructure are responsible for substantial opportunities for growth across the country.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library,  T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
 

A. The market value of Global Radiodermatitis market was $477.48 million in 2019.

A. The forecast period is from 2020 to 2027.

A. The market value of Global Radiodermatitis market in 2020 is $460.48 million.

A. The Global Radiodermatitis market is expected to exhibit significant growth during the forecast period, due to the increasing incedences of cancer, growth in geriatric population, rise in demand of radiation therapy, and increasing prevelance of diabetes, obesity, & other chronic diseases.

A. The base year is 2019 in Global Radiodermatitis market

A. Based on product, the topical segment held a major share in the Global Radiodermatitis market in 2019 and is expected to continue the trend in the forecasting period.

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Radiodermatitis Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library.  T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts